Biotech Values

[DewDiligence]

Re: ARNA vs AMLN in obesity

zebra4o1 is the expert on ARNA’s obesity program in these parts; he’s made several excellent posts you can look up.

I’m waiting to see the definitive Symlin obesity data in non-diabetics. I don’t rule out Symlin as a legitimate candidate just because it’s injected, but the efficacy and safety will have to be above reproach to give it a chance to be successful in the general-purpose obesity market.